Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
Location: East Bay
Please contact Sarah Cardone
Principal Investigator
Related Studies
Cancer Liquid Biopsy Monitoring Study
Investigators: Deepti Behl, MD, Mohammed Kashani-Sabet, M.D.
COVID-19 Impacts on Cancer Care Management, Patient Experience and Care Costs
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D., Cheryl Stults, Ph.D.
Stupski Serious Illness Program Evaluation
Investigator: Sylvia Sudat, PhD
Impact of COVID-19 on Cancer Care Management
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Investigator: Su-Ying Liang, Ph.D.
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: Monique de Bruin, M.D., MPH, External PI, Principal Investigator, Su-Ying Liang, Ph.D.
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D.